Androgen composition for treating an opthalmic condition
The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
1. An ophthalmic emulsion comprising an active ingredient, the active ingredient consisting of a physiologically effective amount of testosterone, and castor oil, wherein said emulsion is suitable for topical administration to an eye; and wherein the testosterone is present in the emulsion in an amount from about 0.01 w/w % to about 0.30 w/w %.
2. The emulsion of claim 1 wherein testosterone is present in the emulsion in an amount from about 0.01 w/w % to about 0.10 w/w %.
3. The emulsion of claim 1 wherein testosterone is present in the emulsion in an amount from about 0.01 w/w % to about 0.05 w/w %.
4. The emulsion of claim 1 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
5. The emulsion of claim 1 , further comprising a solubility enhancing agent.
6. The emulsion of claim 1 wherein the castor oil is present in the emulsion in an amount of about 0.25 w/w %.
7. A method for treating an ocular condition resulting from an androgen deficiency comprising topically administering an effective amount of the ophthalmic composition of claim 1 , wherein said composition is suitable for topical administration to an eye, wherein the ocular condition is blepharitis, and wherein at least one symptom of the ocular condition is alleviated.
8. The method of claim 7 , wherein the carrier in the composition of claim 1 further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, lipophilic vehicle, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
9. The method of claim 7 , wherein the composition of claim 1 further comprises an agent selected from the group consisting of an anti-inflammatory, antibiotic, analgesic, anesthetic, lubricating agent, soothing agent, and a combination thereof.
10. The method of claim 7 , wherein symptoms associated with the ocular condition are reduced.
11. The method of claim 7 , wherein symptoms associated with the ocular condition are eliminated.
12. The method of claim 7 , wherein the administration is repeated until one or more symptoms of the ocular condition are reduced.
13. The method of claim 7 , wherein the administration is repeated until one or more symptoms of the ocular condition are eliminated.
14. The method of claim 7 , wherein the composition is administered to the eye, upper lid, lower lid, and a combination thereof.